Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study-Reference-Cited by-同舟云学术

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Published:2021-11 Issue:11 Volume:22 Page:1560-1572
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yoo Changhoon,Kim Kyu-pyo,Jeong Jae Ho,Kim Ilhwan,Kang Myoung Joo,Cheon Jaekyung,Kang Byung Woog,Ryu Hyewon,Lee Ji Sung,Kim Kyung Won,Abou-Alfa Ghassan K,Ryoo Baek-Yeol

Funder

Servier Institute

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update;Khan;Gut,2012

2. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study;Edeline;J Clin Oncol,2019

3. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study;Primrose;Lancet Oncol,2019

4. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

5. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan;Okusaka;Br J Cancer,2010

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315);Journal of Clinical Oncology;2024-09-10

2. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers;Chinese Medical Journal;2024-09-04

3. New perspectives in biliary tract cancers;ESMO Gastrointestinal Oncology;2024-09

4. Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma;Oncology in Clinical Practice;2024-08-21

5. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial;The Lancet Gastroenterology & Hepatology;2024-08